This isn’t FISHER WALLACE LABORATORIES’s most recent raise. Reg CF · Common Stock · Oct 2026 (Open) is more current.View latest round
via DealMaker · last checked Sep 23, 2026
Raised
$237.7K
100% of ceiling
Investors
—
—
Post-money valuation
$106.2M
pre-money + amount raised
Financials disclosed in this offering
FY2022–FY2023 · hover for source$4.7M
−$7.1M
FY2022
$4.7M
−$7.1M
FY2023
RevenueNet income
Metric
FY2022 audited
FY2023 audited
Income statement
Revenue
$4,739,387
$4,739,387
Cost of goods sold
$1,096,113
$1,096,113
Gross margin
77%
77%
Net income
-$7,073,744
-$7,073,744
Taxes paid
$0
$0
Balance sheet
Cash
$128,229
$128,229
Accounts receivable
$0
$0
Total assets
$439,495
$439,495
Short-term debt
$0
$427,470
Long-term debt
$0
$1,083,664
Total liabilities
$4,664,010
$4,089,159
Other
Headcount
12
3
The fiscal years the issuer disclosed in this offering’s filing, as filed. Full history on the company page.
Deal terms
Pre-money$106M
Post-money$106.2M
Price / share$11.27
Shares offered900
Offering details
Target$10,143
Max—
Min investment—
OpenedJun 11, 2024
DeadlineJul 2, 2024
ClosedJul 2, 2024
Days active21
Links & provenance
Source: SEC EDGAR
0001787792-24-000006
Last synced Sep 23, 2026
0001787792-24-000006
Last synced Sep 23, 2026
About this data. Raised amounts and investor counts come from the platform listing and may lag or be restated; SEC-reported totals can differ until the next Form 1-Z/C-U. Post-money valuation is computed as pre-money plus amount raised and is shown once the round closes — it is not a traded price. Financial statements are as reported by the issuer. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.